These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 36539990

  • 1. Using imaging methods to assess severe calcinosis in juvenile dermatomyositis: A case report.
    Xu H, Wang L, Wei S, Li C, Yuan K.
    Int J Rheum Dis; 2023 Mar; 26(3):554-558. PubMed ID: 36539990
    [Abstract] [Full Text] [Related]

  • 2. Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis.
    Pavlov-Dolijanovic SR, Vujasinovic Stupar NZ, Gavrilov N, Seric S.
    Rheumatol Int; 2014 Nov; 34(11):1615-8. PubMed ID: 24789670
    [Abstract] [Full Text] [Related]

  • 3. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.
    Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG, Childhood Myositis Heterogeneity Study Group.
    Medicine (Baltimore); 2008 Mar; 87(2):70-86. PubMed ID: 18344805
    [Abstract] [Full Text] [Related]

  • 4. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.
    Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG.
    Curr Rheumatol Rep; 2014 Dec; 16(12):467. PubMed ID: 25366934
    [Abstract] [Full Text] [Related]

  • 5. Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial.
    Shiari R, Khalili M, Zeinali V, Shashaani N, Samami M, Moghaddamemami FH.
    Pediatr Rheumatol Online J; 2024 Jan 02; 22(1):2. PubMed ID: 38166943
    [Abstract] [Full Text] [Related]

  • 6. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis.
    Marhaug G, Shah V, Shroff R, Varsani H, Wedderburn LR, Pilkington CA, Brogan PA.
    Rheumatology (Oxford); 2008 Jul 02; 47(7):1031-7. PubMed ID: 18448482
    [Abstract] [Full Text] [Related]

  • 7. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications.
    Harel L, Harel G, Korenreich L, Straussberg R, Amir J.
    J Rheumatol; 2001 May 02; 28(5):1129-32. PubMed ID: 11361202
    [Abstract] [Full Text] [Related]

  • 8. Risk factors for developing calcinosis in juvenile dermatomyositis: subcutaneous and myofascial edema in initial magnetic resonance imaging.
    Yi BY, Marrs J, Acharya P, Sura A, Cidon M.
    Rheumatol Int; 2024 Nov 02; 44(11):2577-2582. PubMed ID: 37432516
    [Abstract] [Full Text] [Related]

  • 9. Juvenile dermatomyositis with bilateral progressive knee flexion contracture.
    Guven M, Gholve PA, Blyakher A, Widmann RF.
    Clin Orthop Relat Res; 2007 Nov 02; 464():238-41. PubMed ID: 17572631
    [Abstract] [Full Text] [Related]

  • 10. Juvenile dermatomyositis forty years on: Case report.
    Rego de Figueiredo I, Guerreiro Castro S, Bernardino V, Silva Nunes J, Alves P, Moraes-Fontes MF.
    Neuromuscul Disord; 2018 Sep 02; 28(9):791-797. PubMed ID: 30064892
    [Abstract] [Full Text] [Related]

  • 11. Calcinosis in juvenile dermatomyositis: a possible role for the vitamin K-dependent protein matrix Gla protein.
    van Summeren MJ, Spliet WG, van Royen-Kerkhof A, Vermeer C, Lilien M, Kuis W, Schurgers LJ.
    Rheumatology (Oxford); 2008 Mar 02; 47(3):267-71. PubMed ID: 18234711
    [Abstract] [Full Text] [Related]

  • 12. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.
    Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW, CARRA Legacy Registry Investigators.
    Pediatr Rheumatol Online J; 2018 Dec 29; 16(1):84. PubMed ID: 30594206
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Multi-center analysis of calcinosis in children with juvenile dermatomyositis].
    Miyamae T, Mori M, Inamo Y, Kohno Y, Takei S, Maeda M, Murata T, Nakata S, Kawai H, Hirano Y, Date Y, Kitamura K, Yokota S.
    Ryumachi; 2003 Jun 29; 43(3):538-43. PubMed ID: 12910962
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
    Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, McHugh NJ, Juvenile Dermatomyositis Research Group.
    Rheumatology (Oxford); 2014 Dec 29; 53(12):2204-8. PubMed ID: 24987158
    [Abstract] [Full Text] [Related]

  • 19. Recovery of Severe Muscular and Fascial Calcinosis After Treatment With Bisphosphonates in a Child With Juvenile Dermatomyositis.
    Cañas CA, Bonilla-Abadía F, Mejía M, Tobón GJ.
    J Clin Rheumatol; 2015 Aug 29; 21(5):267-9. PubMed ID: 26203832
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.